Latest Announcements

Gland Pharma Limited has appointed Mr. Xiao Le as the Chief Investment Officer for its wholly-owned subsidiary, Gland Pharma International Pte. Ltd., effective November 09, 2026. Mr. Xiao Le will be responsible for exploring investment opportunities and improving M&A capability for Gland in the US, China, Singapore, and other countries.

Shyam Metalics and Energy Limited has reaffirmed its credit ratings from CRISIL, with a long-term rating of 'CRISIL AA+/Stable' and a short-term rating of 'CRISIL A1+'. The company's bank debt rating has been enhanced to ₹4,500 Crore, and its ₹50 Crore Commercial Paper programme has been reaffirmed at 'CRISIL A1+'.

Precision Wires India Limited has informed the Exchange about the publication of unaudited standalone financial results for the quarter and half-year ended September 30, 2026, in newspapers. Sagar Systech Limited has published a corrigendum to its unaudited financial results for the quarter ended September 30, 2026, due to an inadvertent clerical error. The company also announced the sale of immovable properties through e-auction.

Shyam Metalics and Energy Ltd reaffirms its credit ratings with CRISIL, with the long-term rating at 'CRISIL AA+/Stable' and short-term rating at 'CRISIL A1+'. The company's bank debt rating has been enhanced to ₹4,500 Crore.

Morepen Laboratories Ltd has announced the launch of its first prescription (Rx) generic product, Desloratadine Tablets USP, in the U.S. market, building on its established API position. The company has also submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Phosphate Tablets USP. Morepen intends to pursue additional U.S. prescription generic filings and distribution opportunities.

Morepen Laboratories Limited has announced the launch of its first prescription (Rx) generic product, Desloratadine Tablets USP, in the U.S. market, building on its established API position. The company has also submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Phosphate Tablets USP.

Muzali Arts Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 14/11/2026 to consider and approve the Unaudited Financial Results for the Second Quarter and Half Year Ended 30th September, 2026.

GCM Capital Advisors Ltd has announced the publication of unaudited financial results for the half year ended September 30, 2026. The results will be hosted on the company's website.

BlueStone Jewellery and Lifestyle Limited has reported a 45% YoY growth in Q3 FY27 (QTD) with a strong festive season performance, driven by buyer transactions and sustained consumer demand.

BlueStone Jewellery and Lifestyle Limited reports a 45% YoY growth in Q3 FY27 (QTD) with a solid festive season performance, driven by buyer transaction growth and improved momentum in product range across entry-level price points.

AMPL Capital Ltd has published its unaudited standalone and consolidated financial results for the quarter and half year ended 30.09.2026, as per Regulation 30 and 47(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

United Van Der Horst Ltd has completed the dispatch of Notice of Postal Ballot to shareholders, as per the captioned subject, and has published the same in newspapers Active Times and Mumbai Lakshadeep.

United Van Der Horst Ltd has announced the publication of its unaudited financial results for the quarter and half year ended September 30, 2026, as per Regulation 47 of SEBI (LODR) Regulation, 2015. The results are available on the company's website and the stock exchange's website.

Arvaya Healthcare Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 13/11/2026 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2026.

Neogen Chemicals Limited has informed the Exchange about the Transcript of the Company’s Q2FY27 Earnings Conference Call held on November 2, 2026. The transcript highlights the company's robust all-round performance during the quarter, with consolidated revenue increasing by 42% year-on-year to INR 296 crore and EBITDA improving by 51% year-on-year to INR 45 crore. The company has also approved the expansion of manufacturing facility at Patancheru, Telangana, and successfully completed its maiden Qualified Institutional Placement (QIP) raising INR 600 crore.

Neogen Chemicals Ltd reported a robust Q2FY27 performance with 42% year-on-year revenue growth to INR 296 crore and 51% year-on-year EBITDA growth to INR 45 crore. The company also announced the expansion of its Organolithium capacity at Patancheru and a successful Qualified Institutional Placement (QIP) raising INR 600 crore.

MphasiS Limited has informed the Exchange regarding the allotment of 152891 shares under Employee Stock Options and Restricted Stock Units plans.

Mphasis Ltd has informed the exchanges that the ESOP Compensation Committee has approved the allotment of 152,891 equity shares against the exercise of employee stock options and restricted stock units under Employee Stock Options Plan 2016 and Restricted Stock Units Plan 2021.

SI Capital & Financial Services Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 to consider and approve the Unaudited Financial Results of the Company for the quarter ending September 30, 2026.

Max Earth Resources Ltd has published its un-audited financial results for the quarter ended September 30, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.